Modulating the Microbiota as a Therapeutic Intervention for Type 2 Diabetes

M. Nazmul Huda1,2†, Myungsuk Kim1,2† and Brian J. Bennett1,2*

1 Department of Nutrition, University of California Davis, Davis, CA, United States, 2 Obesity and Metabolism Research Unit, United States Department of Agriculture (USDA), Agricultural Research Service (ARS), Western Human Nutrition Research Center, Davis, CA, United States

Mounting evidence suggested that the gut microbiota has a significant role in the metabolism and disease status of the host. In particular, Type 2 Diabetes (T2D), which has a complex etiology that includes obesity and chronic low-grade inflammation, is modulated by the gut microbiota and microbial metabolites. Current literature supports that unbalanced gut microbial composition (dysbiosis) is a risk factor for T2D. In this review, we critically summarize the recent findings regarding the role of gut microbiota in T2D. Beyond these associative studies, we focus on the causal relationship between microbiota and T2D established using fecal microbiota transplantation (FMT) or probiotic supplementation, and the potential underlying mechanisms such as byproducts of microbial metabolism. These microbial metabolites are small molecules that establish communication between microbiota and host cells. We critically summarize the associations between T2D and microbial metabolites such as short-chain fatty acids (SCFAs) and trimethylamine N-Oxide (TMAO). Additionally, we comment on how host genetic architecture and the epigenome influence the microbial composition and thus how the gut microbiota may explain part of the missing heritability of T2D found by GWAS analysis. We also discuss future directions in this field and how approaches such as FMT, prebiotics, and probiotics supplementation are being considered as potential therapeutics for T2D.

Keywords: microbiota (16S), type 2 diabetes (T2D), metabolites, probiotics, prebiotics, intermittent fasting, genetics, epigenetics

INTRODUCTION

Diabetes is a metabolic disorder characterized by elevated blood glucose levels. The incidence of diabetes is widespread and the International Diabetes Federation (IDF) reports that 463 million people in the world are suffering from diabetes, which is estimated to reach 700 million by the year 2045 (1). In the USA, 13% of adults aged 18 or older have diabetes (2). Diabetes has been categorized into three classes (type 1, type 2, and gestational diabetes) depending on the underlying pathophysiology. Among them, type 2 diabetes (T2D) accounts for more than 90% of all diabetes (1, 2). Though genetic susceptibility is a critical determinant of T2D, non-genetic
Dysbiosis, Obesity, Low-Grade Inflammation and T2D

A growing number of studies suggest that gut microbiota influences T2D susceptibility, development, severity, and progression. Dysbiosis, an alteration of a healthy microbiota, is associated with obesity, low-grade inflammation, insulin resistance, and T2D which potentially reflects a causal role linking these pathologies (16). Along with animal studies, numerous human cohorts also have reported specific gut bacteria enriched or depleted in T2D patients compared to healthy controls. A summary of the recent reports of altered microbiota found in T2D patients is depicted in Table 1, and the interactions between environmental factors, genetics, microbiota, microbial metabolites, obesity, inflammation, and T2D are shown in Figure 1.

Landmark studies in the 2000s (27–29) demonstrated that the microbiota contributes to digestion, carbohydrate metabolism, obesity, and plasma glucose levels. Additionally, those studies established a causal relationship by showing that the susceptibility to obesity could be transferred between mice when the fecal microbiota of obese mice was transplanted into non-obese animals. Consistent with these findings, several other studies have reported enrichment or depletion of specific obesity-related gut bacteria and indicated a connection between gut microbiota, adiposity, and T2D. For example, increased abundance of Prevotella and decreased abundance of Bacteroides were associated with a higher risk of obesity with metabolic syndrome, while body mass index and body fat percentage were negatively correlated with Coprococcus abundance (30). More recent data suggests that the abundance of a bacteria in the Bacilli family was positively associated with fat mass, and negatively associated with lean mass and plasma glucose level (31). Additionally, Peptostreptococcaceae, Blautia, and a bacterium related to the Clostridiales family were positively associated with plasma glucose levels (31). In a recent randomized, double-blind, placebo-controlled clinical trial with overweight or obese insulin-resistant subjects, pasteurized Akkermansia muciniphila supplementation was associated with weight loss, improved insulin sensitivity, and reduced insulinemia (32). A potential mechanism of these positive effects is an interaction between temperature stable outer membrane protein Amuc 1100 found in pasteurized Akkermansia muciniphila and Toll-like receptor 2 (33).

Obesity and dysbiosis may cause low-grade inflammation (Figure 2) which also contributes to insulin resistance and the development of T2D. Several studies have demonstrated associations between gut microbiota, or microbial components, and low-grade inflammation in T2D (34). An array of bacterial components such as lipopolysaccharides (LPS) (35), flagellin (36), and peptidoglycan (37) can elicit an inflammatory response. LPS binds to immune cell receptors such as Toll-like receptors and Nucleotide Oligomerization Domain (NOD)-like receptors and triggers the expression of proinflammatory mediators that fuel chronic inflammation, promoting metabolic dysregulation and development of T2D (38). The interaction of specific microbes in the gut with the immune system is complex. Some gut bacteria and microbial components promote low-grade inflammation, while others stimulate anti-inflammatory cytokines and chemokines. For example, induction of interleukin (IL)-10 and IL-22 by species of
| Sample size | Age | Sex | Technique | Associated microbiota changes | References |
|-------------|-----|-----|-----------|-------------------------------|------------|
| 183 T2D, 185 Controls (Chinese) | 13–86 | Women (153), Men (209) | Metagenomic sequencing | Increased in T2D: Akkermansia muciniphila, Bacteroides caccae, Clostridium hathewayi, Clostridium ramosum, Clostridium symbiosum, Desulfovibrio sp., Eggerthella lenta, and Escherichia coli | Qin et al. (17) |
| 53 T2D, 49 Impaired glucose tolerance, 43 Controls (Swedish females) | 69–72 | Women (145) | Metagenomic sequencing | Increased in T2D: Clostridium clostridioforme, Lactobacillus gasseri, and Streptococcus mutans | Karlsson et al. (18) |
| 75 T2D, 291 Controls (Danish) | 50–66 | Women (187), Men (179) | Metagenomic sequencing | Decreased in T2D: Clostridium hathewayi, Clostridium bolteae, Clostridium symbiosum, and Roseburia faecis | Wu et al. (20) |
| 46 T2D, 75 Combined glucose intolerance, 178 Impaired glucose tolerance, 189 Impaired fasting glucose, 523 Controls (Swedish) | 57–61 | Women (568), Men (443) | Metagenomic sequencing | Decreased in T2D: Clostridia, Collinsella, Dorea, Prevotella, Ruminococcus, and Vernucocibrio | Zhang et al. (21) |
| 13 T2D, 64 Prediabetes Controls (Chinese) | 52–55 | NA | 16S rRNA V3-V5 region | Increased in T2D: Clostridia, Collinsella, Dorea, Prevotella, Ruminococcus, and Vernucocibrio | Li et al. (22) |
| 98 T2D, 193 Controls (Nigerian) | 41–70 | NA | 16S rRNA V4 region | Decreased in T2D: Clostridia, Collinsella, Dorea, and Fusobacterium | Doumatey et al. (23) |
| 18 T2D, 18 Controls (Danish males) | 31–73 | Men (36) | 16S rRNA V4 region | Increased in T2D: Betaproteobacteria | Larsen et al. (24) |
| 134 T2D, 37 Controls (Chinese) | 45–67 | Women (92), Men (79) | 16S rRNA V3-V4 region | Decreased in T2D: Clostridia, Bacteroides, Clostridium XIVa, Parabacteroides, Staphylococcus, Granulicatella, Porphyromonas, Clostridium XI, Blautia, Anaerostipes, Clostridium XIX, Fusocatenibacter, Enterococcus, Clostridium IX, Eggerthella, and Flavonifractor. Wang et al. (25) |
| 22 T1D, 23 T2D, 23 Controls (Polish) | 20–65 | Women (40), Men (28) | 16S rRNA | Increased: Firmicutes/Bacteroidetes ratio, Vernucocibrio, Ruminococcus | Salamon et al. (26) |

**Table 1** | T2D-related gut microbiota found in human studies.

**Roseburia, Bacteroides, Akkermansia, and Lactobacillus** (33, 39–43) may contribute to restoring insulin sensitivity and improving glucose metabolism (43, 44). Similarly, **Bacteroides thetaiotaomicron, Roseburia intestinalis, Clostridium** clusters IV, and XIVa induce T<sub>reg</sub> cells (45, 46), which are tolerogenic immune cells and are important for maintaining a balance between pro and anti-inflammatory immune responses (47). Additionally, butyrate produced by the gut microbiota enhances colonic T<sub>reg</sub> differentiation through epigenetic modification of histone deacetylase inhibition (48, 49) and is discussed in detail below along with other short-chain fatty acids (SCFAs). Inhibition of pro-inflammatory cytokines and chemokines is another pathway that beneficial microbes use to prevent low-grade inflammation. Various species of

---

**Huda et al. Microbiota and T2D**

Frontiers in Endocrinology | www.frontiersin.org April 2021 | Volume 12 | Article 632335
Lactobacillus, Bacteroides, Roseburia, and Akkermansia can decrease pro-inflammatory cytokines such as IL-1β, IL-6, IL-8, IL-17, and tumor necrosis factor (TNF)-α (40, 50–52). Conversely, Fusobacterium nucleatum and Ruminococcus gnavus can increase inflammatory cytokine production. Therefore, depending on the composition, the gut microbiota may contribute to increased or decreased low-grade inflammation, impacting insulin sensitivity and T2D.

Gut microbiota profiling performed on large cohorts of T2D patients has found the abundance of several bacteria enriched or depleted in T2D subjects compared to controls (Table 1). In general, T2D patients commonly have a decreased abundance of SCFA producing bacteria (Eubacterium rectale, Faecalibacterium prausnitzii, Roseburia intestinalis, Roseburia inulinivorans, Akkermansia, and Bifidobacterium) and tryptophan metabolite producing bacteria (Lactobacillus, Bacteroides, Bifidobacterium, Peptostreptococcus, Ruminococcus, Ruminiclostridium, and Clostridium), and an increased abundance of opportunistic pathogens (Bacteroides caccae and Clostridium hathewayi), branch chain amino acid synthesizing bacteria (Bacteroides vulgatus and Prevotella copri), and sulfate-metabolizing bacteria (Desulfovibrio, Lactobacillus gasseri, and Lactobacillus reuteri) compared to healthy controls (17–22, 26, 53). However, we note that not all the data derived from observational studies have been consistent. For example, one study comparing significant differences in gut microbiota diversity between T2D patients and healthy individuals was conducted on fecal samples from 18 men (24). In this study, decreased Clostridia and increased Bacteroidetes and Proteobacteria were observed, while overall diversity of the gut microbiota was positively correlated with plasma glucose levels in T2D patients. However, these results have not been identified in three large-scale metagenomics analyses performed in Europe and China (17, 18). A decrease in Prevotella was observed in 50 Japanese T2D patients compared to the healthy subjects (53), but in studies of 291 Nigerians and 171 Chinese, increased Prevotella abundance was associated with T2D (23, 25). The reason for the discrepancy between studies may be due to a number of confounding variables such as diet, genetics, medication use, and sequencing techniques. Utilizing alternative approaches and

FIGURE 1 | Factors affecting gut microbiota. The gut microbial composition can be modulated by different interventions such as prebiotics, probiotics, FMT, and intermittent fasting, all of which are considered as potential therapeutics for T2D. Host genetics, epigenetics, and immunity also modulate gut microbiota. Some T2D medication improves circulating glucose levels partly through modulating gut microbiota, which further supports the usability of the gut microbiota as therapeutics for T2D.
Developing new technologies are of critical need to determine which of the associations between the microbiota and T2D are causal and which of the microbial differences are responsive to T2D.

**MICROBIAL METABOLITES**

Beyond the direct effects of bacteria in the microbiota or their components, such as LPS, we now appreciate that the microbiota is a metabolically active “organ” that produces small biomolecules. In the following section, we highlight two important bacteria-derived metabolites TMAO and SCFAs, and briefly comment on other metabolites important for T2D. Gut microbiota is involved in the digestion of food ingredients and produces metabolites supporting physiological function in the human body (54). Microbial metabolites assist our interpretation of the underlying mechanisms by which gut bacterial taxa influence host health and disease (Figure 2 and Table 2).

**Trimethylamine N-Oxide**

Trimethylamine (TMA) is produced by intestinal microbial metabolism of dietary choline and carnitine and is transported to the liver via the portal vein. In the liver, TMA is converted to TMAO by the activity of flavin-containing monoxygenase 3 (FMO3) (70, 71). In vivo studies have identified several candidate microbial taxa associated with TMA/TMAO production including *Anaerococcus hydrogenalis*, *Clostridium asparagiforme*, *C. hathewayi*, *C. sporogenes*, *Desulfovibrio desulfuricans*, *Edwardsiella tarda*, *Escherichia fergusonii*, *Proteus penneri*, and *Providencia rettgeri* (55). TMAO concentrations are elevated in T2D patients, suggesting that this pathway is associated with T2D (72, 73). However, it is not yet clear if the elevated TMAO has a direct causal effect on T2D development or if it is a consequence of T2D. Animal studies have shown that TMAO consumption impairs glucose tolerance by mediating the insulin signaling pathway in the liver and upregulates the expression of pro-inflammatory mediators in adipose tissue (56). Reduction of plasma TMAO by FMO3 knockdown also decreases plasma glucose and insulin levels, whereas FMO3 overexpression increases plasma glucose level and induces insulin resistance (74). A similar relationship between TMAO and T2D may exist in humans as circulating TMAO concentration was found to be significantly higher in T2D patients compared to control subjects observed in a meta-analysis (75). In contrast, a recent Mendelian randomization analysis suggests that elevated circulating TMAO is a consequence of T2D not causal (76). Additional studies on the relationship between TMAO and T2D are needed to clarify these results.

**Short-Chain Fatty Acids**

SCFAs are microbial metabolites produced in the colon and are known to have a wide range of biochemical effects on the host (77).
| Metabolites          | Metabolite production pathway | Metabolite-producing bacteria (genus)                                                                 | Mechanism on T2D risk                                                                                                             | References   |
|---------------------|-------------------------------|-------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------|--------------|
| TMAO                | Choline (diet) -> TMA (intestine) -> TMAO (liver) | • TMA: Anaerococcus, Clostridium, Desulfovibrio, Edwardsiella, Proteus, Providencia, and others      | - Impair glucose tolerance by mediating the insulin signaling pathway in the liver                                                                 | Qi et al. (55) |
|                     |                               | • SCFA: Anaerostipes, Blautia, Coprococcus, Eubacterium, Faecalibacterium, Marvinbryantia, Megasphaera, Roseburia, Ruminococcus, and others | - Increased HOMA-IR, exacerbated the impaired glucose tolerance, and upregulate expression of pro-inflammatory mediators in adipose tissue | Gao et al. (56) |
| SCFA                | Fiber (diet) -> Acetate, propionate, and butyrate (intestine) | • SCFA: Anaerostipes, Blautia, Coprococcus, Eubacterium, Faecalibacterium, Marvinbryantia, Megasphaera, Roseburia, Ruminococcus, and others | - Improve glucose metabolism and energy homeostasis                                                                                   | Morrison et al. (57) |
|                     |                               | • SCFA: Anaerostipes, Blautia, Coprococcus, Eubacterium, Faecalibacterium, Marvinbryantia, Megasphaera, Roseburia, Ruminococcus, and others | - Increase intestinal glucose production and epithelial barrier function by promoting epithelial growth and Bacteroides species | Hirasawa et al. (58) |
|                     |                               | • SCFA: Anaerostipes, Blautia, Coprococcus, Eubacterium, Faecalibacterium, Marvinbryantia, Megasphaera, Roseburia, Ruminococcus, and others | - Regulate the intestinal immune system by binding GPR41, GPR43, and GPR109A                                                                 | Hamer et al. (59) |
|                     |                               | • SCFA: Anaerostipes, Blautia, Coprococcus, Eubacterium, Faecalibacterium, Marvinbryantia, Megasphaera, Roseburia, Ruminococcus, and others | - Reduce plasma glucose level, appetite, insulin secretion, and slow gastric emptying by stimulating GLP-1 and GLP-2 secretion | Ross et al. (60) |
| Imidazole propionate | Histidine (diet) -> Imidazole propionate (intestine) | • Imidazole propionate: Citrobacter, Dickeya, Eggerthella, Lactobacillus, Pectobacterium, Peptostreptococcus, and Streptococcus | - Suppress insulin signaling by mediating the activation of signaling pathways and insulin receptor substrates including rapamycin complex 1 (mTORC1) | Koh et al. (61) |
| Tryptophan metabolites | Tryptophan (diet) -> tryptamine, indole, ILA, IPA, IAA, and skatole (intestine) | • All tryptophan metabolites: Clostridium, • Tryptamine: Ruminococcus, • ILA: Lactobacillus and Bildobacterium, • IPA: Peptostreptococcus, • ILA, IAA, and skatole: Bacteroides | - Reduce plasma glucose level, appetite, insulin secretion, and slow gastric emptying by stimulating GLP-1 secretion                                                                 | Roager et al. (62) |
|                     |                               | • All tryptophan metabolites: Clostridium, • Tryptamine: Ruminococcus, • ILA: Lactobacillus and Bildobacterium, • IPA: Peptostreptococcus, • ILA, IAA, and skatole: Bacteroides | - Enhance the intestinal epithelial barrier by acting on the pregnane X receptor                                                                 | Dodd et al. (63) |
|                     |                               | • All tryptophan metabolites: Clostridium, • Tryptamine: Ruminococcus, • ILA: Lactobacillus and Bildobacterium, • IPA: Peptostreptococcus, • ILA, IAA, and skatole: Bacteroides | - Stimulate gastrointestinal motility by stimulating serotonin secretion                                                                 | Venkatesh et al. (64) |
|                     |                               | • All tryptophan metabolites: Clostridium, • Tryptamine: Ruminococcus, • ILA: Lactobacillus and Bildobacterium, • IPA: Peptostreptococcus, • ILA, IAA, and skatole: Bacteroides | - Activate the immune system by acting on the aryl hydrocarbon receptor                                                                 |               |
|                     |                               | • All tryptophan metabolites: Clostridium, • Tryptamine: Ruminococcus, • ILA: Lactobacillus and Bildobacterium, • IPA: Peptostreptococcus, • ILA, IAA, and skatole: Bacteroides | - Exert anti-inflammatory and anti-oxidative effects in the systemic circulation                                                                 |               |
| Bile acids (BA)     | Cholesterol (liver) -> Primary BA (liver) -> Secondary BA (intestine) | • Secondary BA: Bacteroides, Bildobacterium, Clostridium, Eubacterium, Lactobacillus, Listeria, Peptostreptococcus, and Ruminococcus | - Bind with host nuclear receptors such as FXR (Farnesoid X receptor), PXR (Pregnane X receptor), vitamin D Receptor, RAR-related orphan receptor gamma, and G-protein coupled membrane receptor (TGR-5) and modulate insulin sensitivity, and gluconeogenic genes expression | Jia et al. (65) |
|                     |                               | • Secondary BA: Bacteroides, Bildobacterium, Clostridium, Eubacterium, Lactobacillus, Listeria, Peptostreptococcus, and Ruminococcus | - Bind with host nuclear receptors such as FXR (Farnesoid X receptor), PXR (Pregnane X receptor), vitamin D Receptor, RAR-related orphan receptor gamma, and G-protein coupled membrane receptor (TGR-5) and modulate insulin sensitivity, and gluconeogenic genes expression | Chiang et al. (66) |
|                     |                               | • Secondary BA: Bacteroides, Bildobacterium, Clostridium, Eubacterium, Lactobacillus, Listeria, Peptostreptococcus, and Ruminococcus | - Bind with host nuclear receptors such as FXR (Farnesoid X receptor), PXR (Pregnane X receptor), vitamin D Receptor, RAR-related orphan receptor gamma, and G-protein coupled membrane receptor (TGR-5) and modulate insulin sensitivity, and gluconeogenic genes expression | Zhou et al. (67) |
| BCAA                | Glucose, amino acid (diet) -> BCAA (intestine) | • BCAA: Lactobacillus, Leuconostoc, and Weissella | - Interfer with insulin signaling via phosphorylation of insulin receptor substrate-1 (IRS-1) on serine residue by stimulating rapamycin and its downstream effector, mTOR/S6 kinase | Chen et al. (69) |
|                     |                               | • BCAA: Lactobacillus, Leuconostoc, and Weissella | - Interfer with insulin signaling via phosphorylation of insulin receptor substrate-1 (IRS-1) on serine residue by stimulating rapamycin and its downstream effector, mTOR/S6 kinase | Mutaguchi et al. (173) |
**Anaerostipes**, **Blautia**, **Coprococcus**, **Eubacterium**, **Faecalibacterium**, **Marvinbryantia**, **Megasphaera**, **Roseburia**, and **Ruminococcus** are among the primary gut microbes that produce SCFAs. The SCFAs acetate and butyrate improve glucose homeostasis by inducing intestinal production of glucagon-like peptide-1 (GLP-1) and peptide YY (PYY). These peptides in turn stimulate insulin secretion, suppress appetite, and slow gastric emptying (78–80). GLP-1 is released from colonic enteroendocrine L cells that are distributed along the length of the intestinal epithelium and are in direct contact with the gut microbiota (81). Additionally, SCFAs can regulate the intestinal immune system through G protein-coupled receptors (GPCRs) such as GPR41 and GPR43 (82). Reduced abundance of SCFA producing bacteria was observed in T2D patients suggesting that this pathway is altered in T2D (17, 83). A clinical trial demonstrated that selective enrichment of SCFA producing bacteria, achieved by dietary fiber supplementation, was associated with lower hemoglobin A1c (HbA1c) levels and improved glucose metabolism (84). Stool samples collected prior to and following the intervention were then mechanistically tested via adoptive transfer experiments using mice to establish causality (84). Overall, SCFAs are involved in glucose and lipid metabolism via activation of SCFA receptors (85). Therefore, SCFA could be an intermediate phenotype by which microbiota provides a beneficial effect of T2D prevention.

Besides TMAO and SCFAs there are several other microbial metabolites such as tryptophan catabolites: tryptamine, indole, indolelactic acid [reviewed at (88)], and hydrogen sulfoacetate: acetyl-CoA, pyruvate, and lactate. Bile acids: deoxycholic acid (DCA) and lithocholic acid (LCA) [reviewed at (65, 86)], histidine catabolite: imidazole propionate (Imp) (87), branched-chain amino acids [reviewed at (88)], and hydrogen sulfide (84) have been investigated in the context of T2D (89–92). These microbial metabolites are involved in the regulation of host metabolism, immunity, gene expression, and intestinal integrity, creating an important link between the gut microbiota, and insulin resistance and T2D development. Individually, these results are intriguing but cumulatively the results are complex and heterogeneous. Alterations in the experimental system, environment, diet, or even circadian rhythms (93) all have been implicated as sources of variation contributing to the heterogeneity in the literature. Of particular interest to this review, the overall variation in the microbiota composition was better captured by a 17-day diet history (94). Therefore, information from longitudinal sampling and metabolomics is required to identify precise and dynamic interactions between diet, microbiota, and host.

**INTERACTION BETWEEN HOST GENETICS AND GUT MICROBIOTA ON T2D**

In addition to environmental factors including gut microbiota and microbial metabolites, host genetic architecture is associated with T2D (13). Many studies demonstrate that host genetics influences the community structure of gut microbiota in humans. This opens several interesting hypotheses regarding host-microbe symbiosis and perhaps the microbiota as a mediating variable contributing to the missing heritability in GWAS. More specifically, the contribution of genetic polymorphisms associated with T2D may be partly mediated through gut microbiota. One could wonder if intervention in the gut microbiota may improve T2D in susceptible individuals. Here we provide some recent evidence implicating interactions between host genetics and the microbiome that affect T2D.

Human studies of monozygotic and dizygotic twins have demonstrated that host genetics contribute to the composition of the microbiota (12), by tolerating or rejecting several microbial taxa. For example, the abundance of *Bifidobacterium*, an important commensal bacterium for T2D, is associated with host genotype at the lactase gene locus (LCT, rs4988235, and rs1446585) (95). Individuals with the GG genotype have reduced lactase activity and harbor higher levels of *Bifidobacterium* in their gut. Mechanistically these individuals provide more lactose to the bifidobacteria for utilizing as an energy source, which enriches bifidobacteria in their gut. Establishing if an increase in *Bifidobacterium* due to LCT genotype affects T2D remains to be determined.

In addition to the LCT locus and *Bifidobacterium*, genetic studies are beginning to identify some bacteria associated with specific genetic loci. For example, a recent GWAS found an association between *Ruminococcus* and rs150018970 near the gene RAPGEF1 (96). RAPGEF1 is a signaling protein that transduces signals from GPCRs, which are involved in the regulation of gastrointestinal tract physiology, such as metabolism, immune cell differentiation, and tissue repair (97). Similarly, another study (98) found a quantitative trait locus for *Butyricicoccus* at the locus of SLC5A11 (rs72770483), which encodes a sodium-dependent myo-inositol/glucose co-transporter protein (99). These studies underscore the influence of host genetics on gut microbial colonization. However, further studies will be needed to determine to what extent host genetics affects the gut microbiota and T2D.

In addition to interactions between the host genotype and microbiota composition, we are now beginning to appreciate that microbial metabolites can influence host gene expression through epigenetic mechanisms (15). Thus, there seem to be bi-directional interactions with effects on both the host and specific bacteria of the microbiome. For example, in various tissues, including proximal colon, liver and white adipose tissue, microbial metabolites such as SCFAs influence epigenetic programming by inhibiting histone deacetylase (HDAC) enzyme activity, (100), which promotes de-condensation and relaxation of chromatin and increases chromatin accessibility to transcription factors (101). In particular, *Faecalibacterium prausnitzii* is one of the most abundant anaerobic bacteria in the healthy human gut that produces butyrate. Butyrate targeted inhibition of HDAC1 may have anti-inflammatory effects and ultimately improve insulin sensitivity by downregulating the IL-6/STAT3/IL-17 pathway (102). Butyrate may also influence
differentiation of Th17 and T<sub>reg</sub> cells through enhanced Forkhead Box P3 (Foxp3) expression (102). In human adipose tissue, the epigenetic regulation of the expression of genes involved in glucose and energy homeostasis, such as insulin-like growth factor 2 mRNA binding protein 2 (IGF2BP2), is associated with gut bacterial populations (103). These data support the idea that the gut microbiota could act as an epigenetic regulator in T2D (104). A genome-wide DNA methylation analysis of isolated human pancreatic islet cells harvested from donors with and without T2D revealed 853 unique differential DNA methylation genes, including 17 genes previously identified in GWAS such as TCF7L2, THADA, KCNQ1, FTO, and IRS1 associated with the risk of T2D (105). This reinforces the idea that genetic and epigenetic mechanisms may interact to affect pancreatic β-cell function, development of insulin resistance, and T2D. Understanding if the microbiota specifically aids the host epigenetic changes associated with T2D could be important in the development of novel therapies T2D or comorbidities such as obesity.

**THERAPEUTIC POTENTIAL OF GUT MICROBIOTA FOR T2D**

The associations between gut microbiota, microbial metabolites, and T2D, opened a new perspective for potential novel therapeutics for T2D. Several gut microbiota targeted therapeutics including fecal microbiota transplantation (FMT), medication, and dietary choices could be useful therapeutic strategies to manage T2D (Figure 1). Several clinical trials to evaluate the impact of these potential therapeutic agents on T2D are currently completed or in progress (Table 3).

**Fecal Microbiota Transplantation**

FMT has gained attention over the past few years as a research method demonstrating the contribution of gut microbiota to a disease state. Most clinical trials with FMT have been performed in patients with *Clostridium difficile* infections (106, 107) and these studies have been successful. As an extension of these studies, several additional diseases such as T2D have been suggested responsive to microbiota transplantation (108). In rodent models, insulin sensitivity significantly improved after transferring microbiota in MyD88 deficient NOD mice (109). Similar studies where human microbiota from healthy Chinese subjects are transplanted into diabetic db/db mice remarkably lowers fasting blood glucose concentrations (110). Likewise, transplantation of fecal samples of patients treated with metformin into germ-free mice improves glucose tolerance (111). A limited number of studies have begun to suggest that FMT from lean subjects into patients improves insulin sensitivity which could be in part due to increased butyrate-producing bacteria (108). One study examined the effects of lean donor versus self-FMT on metabolic syndrome patients and found that insulin sensitivity improves significantly at 6-weeks after FMT in male recipients with the metabolic syndrome (112). However, FMT treatment sometimes failed to improve targeted clinical phenotypes. For example, one study failed to show reduced TMAO levels in the recipient of FMT from a vegan donor (112), who have altered intestinal microbiota compared to omnivores (114) and low production of TMAO (115). In addition to inconsistent results, the long-term effects of FMT have not been adequately examined. Thus, further studies are needed to evaluate the long-term effectiveness and potential side-effect of FMT in humans.

**Anti-Diabetic Drugs**

Metformin is a widely known common treatment for T2D but the exact mechanisms underlying the hypoglycemic effect are not yet fully understood. Metformin has been shown to have an inhibitory effect on T2D by activating AMP-activated protein kinase (AMPK) or inhibiting mitochondrial respiration and glycerophosphate dehydrogenase (116–118). Recently, evidence has been reported suggesting that the composition of the gut microbiota mediates the efficacy of metformin to lower blood glucose levels. The fact that intravenous injection of metformin, unlike oral administration, does not lower hyperglycemia, suggests that gut microbiota is an important part of metformin action (119). Indeed, metformin shifts the composition of gut microbiota in both mice and humans, making them more similar to the microbiota of a healthy host (111, 120, 121). Some of these gut microbiota changes have also been seen in healthy people who have not responded to glycemic control to metformin treatment, thus suggesting shifts in the gut microbiota induced by metformin itself, rather than simply reflecting lowered blood glucose level. Metformin influences the abundance of several microbial taxa, including increased abundance of *A. muciniphila, Bifidobacterium bifidum, Bilophila wadsworthia, Escherichia, Lactobacillus, Shigella* spp. as well as a reduced abundance of *Clostridium* spp. and *Intestinibacter* spp. (111, 122, 123). Regarding the effects of these changes on blood glucose, metagenomic analysis of microbial composition demonstrates changes in various functional pathways affecting the production of propionate and butyrate (124, 125). Metformin stimulates the activity of endocrine cells by regulating bile acid conversion, improving intestinal permeability, reducing endotoxin levels, and enhancing the release of GLP-1 and PYY peptides (126). Metformin also decreases the TMA level and the growth of bacteria that produce it in the gut, and thus the circulating TMAO level in mice (127). The fact that transferring the microbiota from metformin-treated mice improves metabolic traits in aged mice indicates that the shifts in the gut microbiota by metformin treatment are beneficial (111). The effect of the microbiota on the efficacy of metformin remains unclear as a recent study found that metformin’s ability to improve T2D in mice was not affected by the elimination of gut microbiota using gnotobiotic mice or antibiotics (128). Although previous studies did not directly demonstrate the role of gut microbiota in improving glycemic control by metformin, it is suggested that the anti-inflammatory activity of metformin could potentially play a role in eliciting some beneficial effects regardless of the gut microbiota.

Another anti-diabetic drug with a link to the microbiota is Acarbose, an α-glucosidase inhibitor. Acarbose suppresses the
### Table 3: Ongoing or completed clinical trials on T2D with FMT, medication, prebiotics/functional foods, or probiotics.

| Category          | NCT Number                  | Title                                                                 | Interventions                              | Country       | Age | Phases | Enrollment |
|-------------------|-----------------------------|----------------------------------------------------------------------|---------------------------------------------|---------------|-----|--------|------------|
| **FMT**           | NCT02346699                | Fecal Microbiota Transplantation for Diabetes Mellitus Type II in Obese Patients | FMT                                         | Israel        | 18–65 | Phase 2 | 30         |
|                   | NCT01790711                | Fecal Microbiota Transplantation on Type 2 Diabetes Mellitus          | FMT                                         | China         | 18–70 | Phase 2| 30         |
|                   | NCT03127696                | Randomized Placebo-controlled Study of FMT to Impact Body Weight and Glycemic Control in Obese Subjects With T2DM | FMT                                         | China         | 18–70 | Phase 3| 61         |
| **Medication**    | NCT03018444                | The Effect of HMG-CoA Reductase Inhibition on Postprandial GLP-1 Secretion | Atorvastatin                               | Denmark       | 18–70 | Phase 1| 15         |
|                   | NCT02900417                | Effect of Sitagliptin on Type 2 Diabetes                             | Sitagliptin                                 | Denmark       | 40–70 | Phase 3| 9          |
|                   | NCT02061124                | Effect of Bile Acid Sequestration on Postprandial GLP-1 Secretion, Glucose Homeostasis and Gut Microbiota | Sevelamer 1600 mg for 7 days                | Denmark       | 35–80 | Phase 3| 50         |
|                   | NCT02960659                | Therapeutic Targets in African-American Youth With Type 2 Diabetes    | Metformin and Liraglutide                  | USA           | 12–25 | Phase 1| 92         |
|                   | NCT04428422                | Effect of Metformin on Gut Microbiota Changes and Glycemic Control of Newly Diagnosed Type 2 Diabetes | Metformin Hydrochloride                     | China         | 18–65 | Phase 4| 52         |
| **Prebiotics/ Functional foods** | NCT03557541 | Sardine-enriched Diet for Prevention Type 2 Diabetes                 | Sardine diet                                | Spain         | 65–70 | Phase 4| 182        |
|                   | NCT035709887               | The Effect of Omega-3 FA on Glucose and Lipid Homeostasis Disorders in Obese/Diabetic Patients | Omega-3 fatty acid                         | Spain         | 50–70 | Phase 4| 900        |
|                   | NCT03194152                | Peanut Consumption and Cardiovascular Disease Risk in a Chinese Population | Peanut                                     | USA           | 20–65 | Phase 1| 238        |
|                   | NCT04403217                | Effect of Mediterranean Diet on the microBIOME of Individuals With Type 2 Diabetes | Individualized structured dietary plan      | Portugal       | 40–80 | Phase 3| 30         |
|                   | NCT02294526                | A Sardine Diet Intervention Study to Assess Benefits to the Metabolic Profile in Type 2 Diabetes Mellitus Patients | Sardine diet                                | Spain         | 40–65 | Phase 3| 35         |
|                   | NCT02717078                | The LoBAG Diet and Type 2 Diabetes Mellitus                          | Diet Therapy                                | USA           | 18–70 | Phase 4| 50         |
|                   | NCT03120379                | The Effect of Omega-3 FA on Hypertriglyceridemia in Patients With T2DM/Ocean). | Omega-3 fatty acid                         | China         | 20–75 | Phase 4| 350        |
|                   | NCT02929901                | The Effects of Coffee Main Constituents (Caffeine and Chlorogenic Acid) Supplementation on Inflammatory, Metabolic Factors, Hepatic Steatosis and Fibrosis in None-Alcoholic Fatty Liver Patients With Type 2 Diabetes | Caffeine and chlorogenic acid               | Iran          | 30–65 | Phase 2| 200        |
|                   | NCT03141710                | Commercial Prebiotic Supplement Study                               | Prebiotics                                  | Scotland       | 18–65 | Phase 4| 12         |
|                   | NCT03552991                | Effects of Dietary Fiber on Glucose Control in Subjects With Type 2 Diabetes Mellitus | Agocur Pregranules                         | South Korea    | 50–    | Phase 1| 14         |
|                   | NCT02974699                | Role of Gastrointestinal Microbes on Digestion of Resistant Starch and Tryptophan Availability to Humans | Potato Starch | | 18–65 | Early| 20         |
| **Probiotics**    | NCT01765517                | Study to Explore the Effects of Probiotics on Endotoxin Levels in Type 2 Diabetes Mellitus Patients | Probiotics                                  | Saudi Arabia   | 20–75 | Phase 3| 83         |
|                   | NCT02728414                | Probiotics Effect on Glucose and Lipid Metabolism and Gut Microbiota in Patients With Type 2 Diabetes | Probiotics                                  | China         | 20–80 | Phase 3| 100        |
|                   | NCT04089280                | Probiotics in Metformin Intolerant Patients With Type 2 Diabetes | Sanprobi Barrier-multispecies probiotics | Poland         | 18–75 | Phase 1| 50         |
|                   | NCT03037918                | Effect of Yakult Ingestion on Diet-induced Insulin Resistance in Humans | Yakult light                               | England        | 18–30 | Phase 1| 56         |
|                   | NCT01250106                | Probiotics as a Novel Approach to Modulate Gut Hormone Secretion and Risk Factors of Type 2 Diabetes and Complications | Lactobacillus reuteri                      | Germany        | 40–65 | Phase 2| 20         |
|                   | NCT04495972                | Intestinimonas for Prevention of Type 2 Diabetes Mellitus             | Intestinimonas-capsules                     | Netherlands    | 18–65 | Phase 1| 26         |

(Continued)
| Interventions | Country | Age | Phases | Enrollment |
|---------------|---------|-----|--------|------------|
| L. reuteri | Sweden | 50–75 | NA | 46 |
| Bifidobacterium animalis A6 | China | 35–68 | Phase 1 | 45 |
| ProMIS probiotics powder | Denmark | 19–40 | Phase 1 | 41 |
| Cow milk | Malaysia | 30–60 | Phase 1 | 12 |
| Camel milk | Sweden | 50–75 | NA | 46 |
| Berberine hydrochloride tablets and ProMetS probiotics powder | China | 20–69 | Phase 3 | 400 |
| Nexium | Denmark | 40–70 | Phase 3 | 200 |
| Lactobacillus reuteri | Malaysia | 30–50 | Early | 100 |
| R. flavefaciens | China | 18–60 | NA | 220 |
| A. muciniphila | Malaysia | 30–65 | Early | 12 |

Continued

These data suggest that the beneficial effects of taking probiotics have been reported, including improving gut health, alleviating symptoms of lactose intolerance, inhibiting the growth of pathogenic bacteria, producing SCFAs, balancing pH, and stimulating the immune system (135). The use of probiotics to manage T2D is of interest, but a limited number of studies have evaluated the effects in clinical settings. Preliminary studies indicated that alteration of the gut microbial composition by probiotics supplementation might improve T2D by reducing pro-inflammatory cytokines, intestinal permeability, and oxidative stress [reviewed at (136)]. Several bacterial species are used in commercial probiotics products, including Bifidobacterium longum subsp. infantis, Lactobacillus, Streptococcus, Pediococcus, and Lactococcus species (137). L. gasseri, Lactobacillus helveticus, Lactobacillus casei, and Bifidobacterium bifidum probiotic reduce fasting blood glucose levels with HbA1c (138–140). Mechanistically, these probiotics have been shown to have antioxidant and immunomodulatory effects by reducing oxidative stress (140), reducing inflammatory molecules, and inhibiting effector functions of CD4+ T-cells (142), which may influence on the reducing blood glucose levels and T2D risk. A randomized, double-blind, placebo-controlled trial of administration of A. muciniphila in overweight/obesity insulin-resistant volunteers improved insulin sensitivity and reduced insulinemia, plasma total cholesterol, body fat mass, hip circumference, and level of blood markers associated with liver dysfunction and inflammation (32). Recent meta-analysis studies showed that the probiotic supplementation improved the fasting blood glucose, HbA1c, and homeostatic model assessment for
insulin resistance (HOMA-IR) in T2D patients and thus can be recommended as complementary advice alongside medicine and lifestyle modifications for T2D treatment (143, 144).

**Prebiotics**

Prebiotics are the non-digestible food ingredients that beneficially affect the host by selectively stimulating the growth and (or) the activity of one or a limited number of bacterial species already resident in the colon (145). Inulin, a linear β-2,1 fructosyl-fructose polydisperse carbohydrate material with or without a α-D-glucose moiety (146), is one of the most studied prebiotics. Inulin-type fructooligosaccharide (ITF) improved glycemia by increasing the production and release of the active forms of GLP-1 from the cecum and proximal colon and reducing plasma ghrelin concentration in the rat (147). The direct effect of inulin supplementation on the T2D is not conclusive in human clinical trials. One study reported that dietary inulin reduced fasting blood glucose, body weights, glycated hemoglobin, plasma LPS, IL-6, TNF-α and IL-17A in T2D patients (148). A recent placebo-controlled crossover clinical trial (149) found enrichment of *Bifidobacterium* and *Bacteroides* with a significantly higher fecal SCFAs concentration due to ITF consumption compared to placebo (150). Additionally, the relative abundance of *Cyanobacteria* and *Bacteroides* is increased, and a reduction in the relative abundance of *Ruminiclostridium*, *Deferribacteres*, and *Tenericutes* is observed due to inulin supplementation, indicating that the dietary inulin alleviates T2D via suppressing inflammation and modulating gut microbiota (148). A recent systemic review (151) has summarized clinical trials conducted to evaluate the effect of dietary inulin on *Akkermansia muciniphila*, which are usually present at a higher abundance in healthy individuals compared to T2D patients and found an increased abundance in the treatment group compared to controls. However, others found no effect largely due to interindividual variation at the baseline T2D phenotypes (152).

It should be noted that a symbiotic mixture of prebiotics and probiotics (134), supplementation could provide a better beneficial effect compared to prebiotic or probiotic alone (153). For example, *Lactobacillus acidophilus* DSM20079 induces 14.5-times more butyrate in the presence of inulin or pectin than glucose (154). Berberine, a natural plant alkaloid extracted from *Berberis aristata* and *Coptis chinensis*, is reported to be an effective remedy for T2D (155). A recent randomized, double-blind, placebo-controlled trial conducted in China demonstrates that administration of berberine with probiotics improves HbA1C levels compared to the group treated with berberine alone (156). A meta-analysis of randomized controlled trials reported that diets supplemented with either prebiotics or symbiotics improved fasting blood glucose and HbA1C in patients with T2D (157). Therefore, symbiotic products that selectively stimulate and (or) activate metabolism of probiotics could be recommended to effectively lower the risk of T2D.

**Intermittent-Fasting**

Intermittent fasting (IF) is defined as a periodic dietary restriction, which has been shown to increase lifespan, and to reduce the risk of developing various age-related pathologies including T2D (158). Animal studies of IF have reported an improvement in body composition, glucose and lipid metabolism, decreased inflammation, and autophagy (159) and gut microbiota might play a pivotal role in this process (160, 161). Though most of the human IF studies show a beneficial effect, the results are not completely conclusive. Two recent reviews summarize the recent literature on the effect of IF on T2D (162, 163). In this portion of the review, we will critically evaluate the microbial aspect of the IF on T2D. A recent study (164) using diabetic mice reported that a 28-day IF intervention re-structured the gut microbiota by increasing the abundance of *Aerococcus*, *Corynebacterium*, *Odoribacter*, and *Lactobacillus* and decreasing the abundance of *Streptococcus*, *Rummeliibacillus*, and *Candidatusarthuritomitu*, which reduced plasma glucose and insulin levels, and improved energy metabolism. The changes in bacterial abundances due to IF are correlated with plasma secondary BAs concentration, increased villi length and reduced gut leakage accompanied by decreased plasma LPS levels (164), indicating improved low-grade inflammation (165). More importantly, the effect of IF on the T2D was suppressed by antibiotics treatment (164), suggesting that the microbiota is a causative agent of improvement in T2D by IF. An alternative to IF is a fasting-mimicking diet (FMD), which contains very low calories and low protein (166). Intermittent administration of FMD led to the reconstruction of gut microbiota by increasing the genera of *Parabacteroides* and *Blautia* while reducing *Prevotellaceae*, *Alistipes*, and *Ruminococcaceae*, along with normalized blood glucose levels, improved insulin sensitivity and β cell function in hyperglycemic db/db mice. This study further underscores that the loss of pancreatic islets and β cells can be prevented by the FMD-mediated altered gut microbiota (167), indicating that FMD improved T2D through pancreatic β cells function. Overall, IF may modulate gut microbiota and improve T2D. However, these findings need to be validated in human cohorts using longitudinal studies to establish the long-term effectiveness of IF in health outcomes including T2D.

**CONCLUDING REMARKS AND FUTURE PERSPECTIVES**

Substantial evidence suggests the gut microbiota, and the metabolites it produces, are critical to the etiology of T2D. A strategy including FMT, medication, prebiotics, probiotics, functional food, and intermittent fasting has been suggested as strategies to reduce T2D. However, most studies have focused on the characterization of gut microbiota rather than functional validation of specific microbial taxa affecting T2D risk. Identifying specific causally related microbial taxa or microbial metabolites responsible for the pathogenesis of T2D could provide interesting new opportunities for the diagnosis, treatment, and prevention of T2D.

Recently several novel approaches have been taken to directly modify the gut microbiota. For example, one study (168) reported a novel approach to remodeling the gut microbiota using cyclic d,l-α-peptides. Alternatively, the FXR agonist
fexaramine, which was not absorbed by the intestine, binds the FXR receptor on intestinal cells and induces enteric fibroblast growth factor 15 that leads to alterations in bile acid composition, reduces diet-induced weight gain, body-wide inflammation, and hepatic glucose production (169). These studies suggest that the development of therapeutics targeting the microbiome instead of the host is a viable strategy for T2D.

As discussed above, probiotic supplementation and FMT studies have established a causal relationship between gut microbiota and T2D. However, studies (170, 171) using FMT demonstrated that the relationship between gut microbiota and disease phenotype is more complex than usual thought. For example, FMT may not always be able to transfer the beneficial clinical phenotype, instead sometimes can be resulted in a detrimental opposite effect. A recent FMT study (31) in which the gut microbiota of C57BL/6J mice ablated using antibiotics was reconstituted with either C57BL/6J or WSB/EiJ fecal microbiota. C57BL/6J mice are more susceptible to obesity, diabetes, and atherosclerosis compared to WSB/EiJ mice (170). Paradoxically, mice reconstituted with WSB/EiJ microbiota had significantly higher fat mass compared to the mice reconstituted with C57BL/6J microbiota. Moreover, among the members of gut microbiota, only the bacterial community is being studied extensively. To date, enteric virus, fungal, or archaea communities are still underappreciated mostly because of the assay difficulties and lack of standard reference databases and thus their contribution to T2D remains largely unknown. Therefore, incorporating these members in analysis may potentially lead to the development of novel therapeutics for T2D.

Computational approaches such as machine learning facilitate the analysis of large “-omics” datasets through the development of algorithms and mathematical models designed to predict outcomes. It remains to be determined how these novel computational approaches can be harnessed to further our understanding of the microbiota’s role in T2D but initial studies are promising. Recently two studies used machine learning tools to explore the role of the microbiome in precision nutrition (172) and to predict cirrhosis based on gut-microbiota features (173). Thus, use of these novel computational approaches may further our understanding of the metabolic consequences of how alterations in dietary habits, microbiota, metabolomics, genetics, and epigenetics, interact to alter metabolism. A better understanding of the interactions between microbiota, lifestyle, and host factors such as genetics and epigenetics might lead to a novel therapeutic approach for T2D.

AUTHOR CONTRIBUTIONS

BB supervised all portions of the review process, interpreted the results, and mentored manuscript writing. MH and MK conducted the literature search, extracting the information, and drafting the manuscript. MH and MK also addressed co-authors’ comments and concerns. BB, MH, and MK critically revised the manuscript. BB had primary responsibility for the final content. All authors contributed to the article and approved the submitted version.

FUNDING

This research was supported in part by NIH grant 5R01HL128572 (BB), NIFA grant 2019-07731 (BB) and USDA project 2032-51530-025-00D (BB). The USDA is an equal-opportunity employer.

ACKNOWLEDGMENTS

The figures were created by using tools available at BioRender.com.

REFERENCES

1. IDF. IDF Diabetes Atlas. 9th Vol. 2019. Brussels, Belgium: International Diabetes Federation (2019).
2. Control C?D. Prevention. National diabetes statistics report, 2020. Atlanta, GA: Centers for Disease Control and Prevention, US Department of Health and Human Services (2020).
3. Berg G, Rybakova D, Fischer D, Cernava T, Vergès M-CC, Charles T, et al. Microbiome definition revisited: old concepts and new challenges. Microbiome (2020) 8(1):103. doi:10.1186/s40168-020-00875-0
4. Savage DC. Microbial ecology of the gastrointestinal tract. Annu Rev Microbiol (1977) 31(1):107–33. doi:10.1146/annurev.mi.31.100177.000543
5. Ju F, Zhang T. 16S rRNA gene high-throughput sequencing data mining of microbial diversity and interactions. Appl Microbiol Biotechnol (2015) 99 (10):4119–29. doi:10.1007/s00253-015-6536-y
6. Thomas T, Gilbert J, Meyer F. Metagenomics-a guide from sampling to data analysis. Microbial Inf Experiment (2012) 2(1):3. doi:10.1186/2042-5783-2-3
7. Sekirov I, Russell SL, Antunes LC, Finlay BB. Gut microbiota in health and disease. Physiol Rev (2010) 90(3):859–904. doi:10.1152/physrev.00045.2009
8. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature (2006) 444(7122):1022–3. doi:10.1038/4441022a
9. Tilg H, Zmora N, Adolph TE, Elinav E. The intestinal microbiota fuelling metabolic inflammation. Nat Rev Immunol (2020) 20(1):40–54. doi:10.1038/s41577-019-0198-4
10. Gurung M, Li Z, You H, Rodrigues R, Jump DB, Morgun A, et al. Role of gut microbiota in type 2 diabetes pathophysiology. EBioMedicine (2020) 51:102590. doi:10.1016/j.ebiom.2019.11.051
11. Gölden E. Lifestyle factors affecting the gut microbiota’s relationship with type 1 diabetes. Curr Diabetes Rep (2018) 18(11):111. doi:10.1007/s11892-018-1098-x
12. Goodrich J, Waters JL, Poole AC, Sutter JL, Koren O, Blekhman R, et al. Human genetics shape the gut microbiome. Cell (2014) 159(4):789–99. doi:10.1016/j.cell.2014.09.053
13. Fuchsberger C, Flannick J, Teslovich TM, Mahajan A, Agarwala V, Gaulton KJ, et al. The genetic architecture of type 2 diabetes. Nature (2016) 536(7614):41–7. doi:10.1038/nature18642
14. Maher B. The case of the missing heritability: when scientists opened up the human genome, they expected to find the genetic components of common traits and diseases. But they were nowhere to be seen. Brendan Maher shines
a light on six places where the missing loot could be stashed away. Nature (2008) 456(7218):18–22. doi: 10.1038/45618a
15. Qin Y, Wade PA. Crossstalk between the microbiome and epigenome: messages from bugs. J Biochem (2018) 163(2):105–12. doi: 10.1039/bh0mv080
16. Sircana A, Framarin L, Leone N, Berrutti M, Castellino F, Parente R, et al. Altered Gut Microbiota in Type 2 Diabetes: Just a Coincidence? Curr Diabetes Rep (2018) 18(10):98. doi: 10.1007/s11892-018-1057-6
17. Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature (2012) 490(7418):55–60. doi: 10.1038/nature11450
18. Karlsson FH, Tremaroli V, Nookaew I, Bergstrom G, Behre CJ, Fagerberg R, et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature (2013) 498(7452):99–103. doi: 10.1038/nature12198
19. Pedersen HK, Gudmundsdottir V, Nielsen HB, Hyotylainen T, Nielsen T, Jensen BA, et al. Human gut microbes impact host serum metabolome and insulin sensitivity. Nature (2016) 535(7612):376–81. doi: 10.1038/ nature18464
20. Wu H, Tremaroli V, Schmidt C, Lundqvist A, Olsson LM, Kramer M, et al. The Gut Microbiota in Prediabetes and Diabetes: A Population-Based Cross-Sectional Study. Cell Metab (2020) 32(3):379–90 e3. doi: 10.1016/j.cmet.2020.06.011
21. Zhang X, Shen D, Fang Z, Jie Z, Qiu X, Zhang C, et al. Human gut microbiota changes reveal the progression of glucose intolerance. PloS One (2013) 8(8):e71108. doi: 10.1371/journal.pone.0071108
22. Li Q, Chang Y, Zhang K, Chen H, Tao S, Zhang Z. Implication of the gut microbiome composition of type 2 diabetic patients from northern China. Sci Rep (2020) 10(1):5450. doi: 10.1038/s41598-020-62224-3
23. Doumatey AP, Adeyemo A, Zhou J, Lei L, Adebamowo SN, Adebamowo C, et al. Enterotype Bacteroides Is...
with type 2 diabetes. Diabetes Care (2014) 37(8):2343–50. doi: 10.2337/dc13-2817
54. Kostt KP, Gratz SW, Sheridan PO, Flint HJ, Duncan SH. The influence of diet on the gut microbiota. Pharmacol Res (2013) 69(1):52–60. doi: 10.1016/j.phrs.2012.10.020
55. Qi J, You T, Li J, Pan T, Xiang L, Han Y, et al. Circulating trimethylamine N-oxide and the risk of cardiovascular diseases: a systematic review and meta-analysis of 11 prospective cohort studies. J Cell Mol Med (2018) 22(1):185–94. doi: 10.1111/jcm.13307
56. Gao X, Liu X, Xu J, Xue C, Xue Y, Wang Y. Dietary trimethylamine N-oxide exacerbates impaired glucose tolerance in mice fed a high fat diet. J Biosci Bioeng (2014) 118(4):476–81. doi: 10.1016/j.jbiosc.2014.03.001
57. Morrison DJ, Preston T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes (2016) 7(3):189–200. doi: 10.1080/19490976.2015.1134082
58. Hirasawa A, Hara T, Katsuma S, Adachi T, Tsujimoto G. Free fatty acid receptors and drug discovery. Biol Pharm Bull (2008) 31(10):1847–51. doi: 10.1248/bpb.31.1847
59. Hamer HM, Jonkers D, Venema K, Ryu SH, Molinaro A, et al. Microbial tryptophan catabolites in health and disease. Trends Microbiol (2018) 26(6):313–22. doi: 10.1016/j.tim.2018.01.009
60. Ross SA, Ekoe J. Incretin agents in type 2 diabetes. Curr Diabetes Rep (2012) 12:279–85. doi: 10.1007/s11892-012-0279-3
61. Koh A, Mannerås-Holm L, Yunn NO, Nilsson PM, Ryu SH, Molinaro A, et al. Microbial Imidazole Propionate Affects Responses to Metformin and Metformin-Based Therapies. Cell Metab (2014) 20(5):901–12. doi: 10.1016/j.cmet.2014.03.003
62. Roager HM, Licht TR. Microbial tryptophan catabolites in health and disease. Nat Commun (2018) 9(1):1–9. doi: 10.1038/s41467-018-05470-4
63. Veenhuis M, Tjalsma H, Hylemon PB. Bile acids are nutrient signaling hormones. Nat Rev Endocrinol (2015) 11(3):139–51. doi: 10.1038/nrendo.2014.156
64. Venkatesh M, Mukherjee S, Wang H, Li H, Sun K, Benechet AP, et al. Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, is regulated by gut microbiota via bile acid signaling. J Cell Physiol (2017) 232(7):1747–55. doi: 10.1002/jcp.25369
65. Butler CL, Rowan CM, Lacy AM, et al. The role of butyrate on colonic function. Ther Adv Gastroenterol (2011) 4(3):189–96. doi: 10.1177/1758882911401161
66. Jia J, Dou P, Gao M, Kong X, Li C, Liu Z, et al. Assessment of Causal Direction Between Gut Microbiota-Dependent Metabolites and Cardiometabolic Health: A Bidirectional Mendelian Randomization Analysis. Diabetes (2018) 67(9):1747–55. doi: 10.2337/db18-0153
67. Torres RE, Melian K, Moreno A, Alonso J, Sabatier CA, Hernandez M, et al. Prevalence of vacA, cagA and babA2 genes in Cuban Helicobacter pylori isolates. World J Gastroenterol (2009) 15(2):204–10. doi: 10.3748/wjg.v15.i20.204
68. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev (2007) 87(4):1409–39. doi: 10.1152/physrev.00034.2006
69. Erard A, Cani PD. Gut microbiota and GLP-1. Rev Endocrine Metab Disord (2014) 15(3):189–96. doi: 10.1007/s11154-014-9288-6
70. Parnell JA, Reimer RA. Weight loss during olfactory supplementation is associated with decreased ghrelin and increased peptide YY in overweight and obese adults. Ann J Clin Nutr (2009) 89(6):1751–9. doi: 10.3945/ajcn.2009.27465
71. Chimerel C, Emery E, Summers DK, Keyser U, Griibele FM, Reimann F. Bacterial metabolite bile acid modulates incretin secretion from intestinal enteroendocrine l cells. Cell Rep (2014) 9(4):1202–8. doi: 10.1016/j.celrep.2014.10.032
72. Macia L, Thorburn AN, Bingi LC, Marino E, Rogers KE, Maaslowski KM, et al. Microbial influences on epithelial integrity and immune function as a basis for inflammatory diseases. Immunol Rev (2012) 245(1):164–76. doi: 10.1111/j.1600-065X.2011.01080.x
73. Dangre DJ, Bailey CJ, Pearson ER. Metformin and the gastrointestinal tract. Diabetologia (2016) 59(3):346–55. doi: 10.1007/s00125-015-3844-9
74. Zhao L, Zhang F, Ding X, Wu G, Lam YY, Wang X, et al. Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes. Science (2016) 359(6380):1151–6. doi: 10.1126/science.aao5774
75. Mandaluia DK, Seshadri S. Short Chain Fatty Acids, pancreatic dysfuncstion and type 2 diabetes. Pancreatology (2019) 19(2):280–4. doi: 10.1016/j.jpan.2019.01.021
76. Gérard P. Metabolism of cholesterol and bile acids by the gut microbiota. Pathogens (2014) 3(1):1–24. doi: 10.3390/pathogens3010014
77. Koh A, Molinaro A, Stahlman M, Khan MT, Schmidt C, Molinaro L, et al. Microbially Produced Imidazole Propionate Impairs Insulin Signaling through mTORC1. Cell (2018) 175(4):947–61.e17. doi: 10.1016/j.cell.2018.09.035
78. Bloomgarden Z. Diabetes and branched-chain amino acids: What is the link? J Diabetes (2018) 10(5):330–2. doi: 10.1111/1753-0473.12645
79. Katsuma S, Hirasawa A, Tsujimoto G. Bile acid promotes glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem Biophys Res Commun (2005) 329(1):386–90. doi: 10.1016/j.bbrc.2005.01.139
80. Chen M-I, Yi L, Zhang Y, Zhou X, Ran L, Yang J, et al. Resveratrol attenuates trimethylamine-N-oxide-induced atherosclerosis by regulating TMAO synthesis and bile acid metabolism via remodeling of the gut microbiota. MBio (2016) 7(2):e02110–15. doi: 10.1128/mBio.02110-15
81. Newgard CB, An J, Bain JR, Muelhbaier MJ, Stevens RD, Lien LF, et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab (2009) 9(4):311–26. doi: 10.1016/j.cmet.2009.02.002
82. Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, et al. Metabolite profiles and the risk of developing diabetes. Nat Med (2011) 17(4):488–503. doi: 10.1038/nm.2307
83. Thaisse CA, Itat S, Rothschild D, Meijer MT, Levy M, Moresi C, et al. Persistent microbiome alterations modulate the rate of post-dieting weight regain. Nature (2016) 540(7634):544–51. doi: 10.1038/nature20796
84. Johnson AJ, Vangay P, Al-Ghalib GA, Hillmann BM, Ward TL, Shields-Cutler RR, et al. Daily Sampling Reveals Personalized Diet-Microbiome Associations in Humans. Cell Host Microbe (2019) 25(6):789–802. doi: 10.1016/j.chom.2019.05.005
95. Goodrich JK, Davenport ER, Beaumont M, Jackson MA, Knight R, Ober C, et al. Genetic determinants of the gut microbiome in UK twins. Cell Host Microbe (2016) 19(5):731–43. doi: 10.1016/j.chom.2016.06.017

96. Hughes DA, Racigalepe R, Wang J, Ruhlemann MC, Tito RY, Falony G, et al. Genome-wide associations of human gut microbiome variation and implications for causal inference analyses. *Nat Microbiol* (2020) 5(9):1079–87. doi: 10.1038/s41564-020-0743-8

97. Cohen LJ, Esterhazy D, Kim S-H, Lemetre C, Aguilar RR, Gordon EA, et al. Commensal bacteria make GPCR ligands that mimic human signalling molecules. *Nature* (2017) 549(7670):48–53. doi: 10.1038/nature23874

98. Consortium G. The Genotype-Tissue Expression (GTEx) pilot analysis: multtissue gene regulation in humans. *Science* (2015) 348(6235):648–60. doi: 10.1126/science.1262533

99. Coady MJ, Wallendoff B, Gagnon DG, Lapointe J-Y. Identification of a novel Na+-myo-inositol cotransporter. *J Biol Chem* (2002) 277(38):35219–24. doi: 10.1074/jbc.M204321200

100. Krautkramer KA, Kreznar JH, Romano KA, Vivas EI, Barrett-Wilt GA, Zhou L, Zhang M, Wang Y, Dorfman RG, Liu H, Yu T, et al. Epigenetic metabolite makers of obesity独立于肠道微生物。*Nature* (2013) 5(15):619–622.

101. Kootte RS, Levin E, Salojarvi K, Smiths LP, Hartstra AV, Udayappan SD, et al. Improvement of Insulin Sensitivity after Lean Donor Feces in Metabolic Syndrome Is Driven by Baseline Intestinal Microbiota Composition. *Cell Metab* (2017) 26(4):611–9.e6. doi: 10.1016/j.cmet.2017.09.008

102. Smiths LP, Kootte RS, Levin E, Prudan A, Fuentes S, Zoetendal EG, et al. Effect of vegan fecal microbiota transplantation on carnitine-and choline-derived trimethylamine-N-oxide production and vascular inflammation in patients with metabolic syndrome. *J Am Heart Assoc* (2018) 7(7):e008342. doi: 10.1161/JAHA.117.008342

103. Watson MM, Søreide K. The Gut Microbiota Influence on Human Endocrine System, and Pavesie). *Diabetes Metab Res Rev* (2017) 317(6):E1121. doi: 10.1002/dmrr.2975

104. Ejtahed HS, Tito RY, Siadat SD, Hasani-Ranjbar S, Hoseini-Tavassol Z, Rymbens L, et al. Metformin induces weight loss associated with gut microbiota alteration in non-obese diabetic women: a randomized double-blind clinical trial. *Eur J Endocrinol* (2019) 180(3):165–76. doi: 10.1530/EJE-18-0826

105. Rosario D, Benfeitas R, Bidkhori G, Zhang C, Uhlen M, Shoaie S, et al. Understanding the Representative Gut Microbiota Dysbiosis in Metformin-Treated Type 2 Diabetes Patients Using Genome-Scale Metabolic Modeling. *Front Physiol* (2018) 9:775. doi: 10.3389/fphys.2018.00775

106. Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal microbiota transplantation for Clostridioides difficile infection: a safe and effective treatment for recurrent *Clostridiodes difficile* infection: A case report. *Pediatr Transplant* (2020) 24(1):e13598. doi: 10.1111/petr.13598

107. Khoruts A, Sadovsky M. Understanding the mechanisms of faecal microbiota transplantation. *Nat Rev Gastroenterol Hepatol* (2015) 348(6235):648–60. doi: 10.1126/science.1262533

108. Kootte RS, Levin E, Salojarvi K, Smiths LP, Hartstra AV, Udayappan SD, et al. Improvement of Insulin Sensitivity after Lean Donor Feces in Metabolic Syndrome Is Driven by Baseline Intestinal Microbiota Composition. *Cell Metab* (2017) 26(4):611–9.e6. doi: 10.1016/j.cmet.2017.09.008

109. Smiths LP, Kootte RS, Levin E, Prudan A, Fuentes S, Zoetendal EG, et al. Effect of vegan fecal microbiota transplantation on carnitine-and choline-derived trimethylamine-N-oxide production and vascular inflammation in patients with metabolic syndrome. *J Am Heart Assoc* (2018) 7(7):e008342. doi: 10.1161/JAHA.117.008342

110. Wu GD, Compner C, Chen EZ, Smith SA, Shah RD, Bittinger K, et al. Comparative metabolomics in vegans and omnivores reveal constraints on diet-dependent gut microbiota metabolism production. *Gut* (2016) 65(1):63–72. doi: 10.1136/gutjnl-2014-308209

111. Zhou L, Zhang M, Wang Y, Dorfman RG, Liu H, Yu T, et al. Epigenetic metabolite makers of obesity independent of the gut microbiota. *Nature* (2013) 5(15):619–622.

112. Kootte RS, Levin E, Salojarvi K, Smiths LP, Hartstra AV, Udayappan SD, et al. Improvement of Insulin Sensitivity after Lean Donor Feces in Metabolic Syndrome Is Driven by Baseline Intestinal Microbiota Composition. *Cell Metab* (2017) 26(4):611–9.e6. doi: 10.1016/j.cmet.2017.09.008

113. Smiths LP, Kootte RS, Levin E, Prudan A, Fuentes S, Zoetendal EG, et al. Effect of vegan fecal microbiota transplantation on carnitine and choline-derived trimethylamine-N-oxide production and vascular inflammation in patients with metabolic syndrome. *J Am Heart Assoc* (2018) 7(7):e008342. doi: 10.1161/JAHA.117.008342

114. Wu GD, Compner C, Chen EZ, Smith SA, Shah RD, Bittinger K, et al. Comparative metabolomics in vegans and omnivores reveal constraints on diet-dependent gut microbiota metabolism production. *Gut* (2016) 65(1):63–72. doi: 10.1136/gutjnl-2014-308209
132. Zhang Q, Xiao X, Zheng J, Li M, Yu M, Ping F, et al. Featured article: Structure modulation of gut microbiota in liraglutide-treated diabetic male rats. Exp Biol Med (Maywood) (2018) 243(1):34–44. doi: 10.1177/1535370217743675

133. Wang L, Li P, Tang Z, Yan X, Feng B. Structural modulation of the gut microbiota and the relationship with body weight: compared evaluation of liraglutide and saxagliptin treatment. Sci Rep (2016) 6:33251. doi: 10.1038/srep33251

134. Schrezenmeir J, de Vrese M. Probiotics, prebiotics, and synbiotics—approaching a definition. Am J Clin Nutr (2001) 73(2 Suppl):S361–4. doi: 10.1093/ajcn/73.2.S361s

135. Markowiak P, Sliżewska K. Effects of probiotics, prebiotics, and synbiotics on human health. Nutrients (2017) 9(9):1021. doi: 10.3390/nu9091021

136. Kim YA, Keogh JB, Clifton PM. Probiotics, prebiotics, synbiotics and insulin sensitivity. Nutr Rev (2018) 76(1):31–51. doi: 10.1093/nutrev/bny0018X

137. Kechagia M, Basoulis D, Konstantopoulou S, Dimitriadi D, Gyftopoulou K, et al. The effect of prebiotics and synbiotics on the gut microbiota in T2D individuals. Front Endocrinol (2018) 9:28. doi: 10.3389/fendo.2018.00028

138. Wang L, Li P, Tang Z, Yan X, Feng B. Structural modulation of the gut microbiota: introducing the concept of prebiotics. J Nutr (2021) 152(8):2559–65. doi: 10.1093/jn/nxab063

139. Yun S, Park H, Kang J. Effect of Lactobacillus gasseri BNR17 on blood glucose levels and body weight in a mouse model of type 2 diabetes. Anaerobe (2017) 19:192–8. doi: 10.1016/j.anaerobe.2015.12.008

140. Hove KD, Brons C, Faerch K, Lund SS, Rossing P, Vaag A. Effects of 12 weeks of treatment with fermented milk on blood pressure, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes: a randomized, double-blind placebo-controlled study. Eur J Endocrinol (2015) 172(1):1–20. doi: 10.1530/EJE-14-0554

141. Villarini M, Caldini G, Moretti M, Trotta F, Pasquini R, Cenci G. Modulatory effects of the gut microbiota on body composition in overweight and obese patients. Diabetologia (2019) 62(9):1992–2003. doi: 10.1007/s00125-019-05269-x

142. Sharma P, Bhardwaj P, Singh R. Administration of Lactobacillus casei and Bifidobacterium bifidum Ameliorated Hyperglycemia, Dyslipidemia, and Oxidative Stress in Diabetic Rats. Int J Prev Med (2016) 7:102. doi: 10.4103/2008-7802.188870

143. Kasinska MA, Drzewoski J. Effectiveness of probiotics in type 2 diabetes: a systematic review and meta-analysis. Nutrients (2018) 10(10):1356. doi: 10.3390/nu10101356

144. Bock PM, Telo GH, Ramalho R, Sbaraini M, Leivas G, Martins AF, et al. The effect of probiotics on body composition and substrate metabolism in men with type 2 diabetes. Diabetes Res Clin Pract (2015) 107(5):1681–7. doi: 10.1016/j.diabres.2015.05.012

145. Anson RM, Guo Z, deason RM, Vu TD, Rios M, Hagepanos A, et al. Intermittent fasting dissociates beneficial effects of dietary restriction on glucose metabolism and neuronal resilience to injury from calorie intake. Proc Natl Acad Sci USA (2016) 113(30):E5372–80. doi: 10.1073/pnas.1607821113

146. Chen PB, Black AS, Sobel AL, Zhao Y, Mukherjee P, Molparia B, et al. Directed remodeling of the mouse gut microbiota improves the development of atherosclerosis. Nat Biotechnol (2020) 38(11):1288–97. doi: 10.1038/s41587-020-0459-5

147. Liu Z, Dai X, Zhang H, Shi R, Hui Y, Jin X, et al. Gut microbiota mediates intestinal-fat-tasting alleviation of diabetes-induced cognitive impairment. Sci Rep (2019) 9(1):1. doi: 10.1038/s41598-018-27228-4

148. de Cabo R, Mattson MP. Effects of Intermittent Fasting on Health, Aging, and Disease. N Engl J Med (2019) 381(25):2541–51. doi: 10.1056/NEJMra1905136

149. Zhang Y, Gu Y, Ren H, Wang S, Zhong H, Zhao X, et al. Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study). Nat Commun (2020) 11(1):5015. doi: 10.1038/s41467-020-18444-8

150. McRorie JW, Gibb RD, McKeown NM. Inulin-type fructans have no significant beneficial effects on lipid or glucose metabolism. Eur J Clin Nutr (2017) 71(5):677. doi: 10.1038/ejcn.2017.15

151. McRorie JW, Gibb RD, McKeown NM. Inulin-type fructans have no significant beneficial effects on lipid or glucose metabolism. Eur J Clin Nutr (2017) 71(5):677. doi: 10.1038/ejcn.2017.15
171. Mell B, Jala VR, Mathew AV, Byun J, Waghulde H, Zhang Y, et al. Evidence for a link between gut microbiota and hypertension in the Dahl rat. *Physiol Genomics* (2015) 47(6):187–97. doi: 10.1152/physiolgenomics.00136.2014

172. Berry SE, Valdes AM, Drew DA, Asnicar F, Mazidi M, Wolf J, et al. Human postprandial responses to food and potential for precision nutrition. *Nat Med* (2020) 26(6):964–73. doi: 10.1038/s41591-020-0934-0

173. Oh TG, Kim SM, Caussy C, Fu T, Guo J, Bassirian S, et al. A Universal Gut-Microbiome-Derived Signature Predicts Cirrhosis. *Cell Metab* (2020) 32 (5):878–88. doi: 10.1016/j.cmet.2020.06.005

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

*Copyright © 2021 Huda, Kim and Bennett. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*